|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Optimal operation by controllable loads based on smart grid topology considering insolation forecasted error显示文摘 | Kenichi Tanaka Kosuke Uchida Kazuki Ogimi | 2011 | IEEE Transactions on Smart Grid2011，2，3： | 1 |
| 2 | Rituximab and cyclosporine therapy for accelerated phase Chediak-Higashi syndrome显示文摘 | Ogimi C Tanaka R Arai T | | 0，，04： | 1 |
| 3 | Mycophenolatemofetil therapy for juvenile dermatomyositis with immunethrombocytopenic purpura显示文摘 | Ogimi C Honma N Tanaka R Oh-ishi T | 2012 | Mod Rheumatol2012，22，2： | 1 |
| 4 | Optimal Operation by Controllable Loads Based on Smart Grid Topology Considering Insolation Forecasted Error显示文摘 | Tanaka K Uchida K Ogimi K | 2011 | Smart Grid2011，2，3： | 1 |
| 5 | Spinal epidural metastasis from pineal germinoma显示文摘 | Tosaka M Ogimi T Itoh H | 2003 | Acta Neurochir2003，145，5： | 1 |
| 6 | Mycophenolate mofetil therapy for juvenile dermatomyositis with immune thrombocytopenic purpura 显示文摘 | Ogimi C Honma N Tanaka R | 2012 | Mod Rheumato12012，22，2： | 1 |
| 7 | Evaluation of bacterial contamination and medium-term oncological outcomes of intracorporeal anastomosis for colon cancer:A propensity score matching analysis显示文摘BACKGROUND Although intracorporeal anastomosis(IA)for colon cancer requires longer operative time than extracorporeal anastomosis(EA),its short-term postoperative results,such as early recovery of bowel movement,have been reported to be equal or better.As IA requires opening the intestinal tract in the abdominal cavity under pneumoperitoneum,there are concerns about intraperitoneal bacterial infection and recurrence of peritoneal dissemination due to the spread of bacteria and tumor cells.However,intraperitoneal bacterial contamination and medium-term oncological outcomes have not been clarified.abdominal cavity in IA.METHODS Of 127 patients who underwent laparoscopic colon resection for colon cancer from April 2015 to December 2020,75 underwent EA(EA group),and 52 underwent IA(IA group).After propensity score matching,the primary endpoint was 3-year disease-free survival rates,and secondary endpoints were 3-year overall survival rates,type of recurrence,surgical site infection(SSI)incidence,number of days on antibiotics,and postoperative biological responses.RESULTS Three-year disease-free survival rates did not significantly differ between the IA and EA groups(87.2%and 82.7%,respectively,P=0.4473).The 3-year overall survival rates also did not significantly differ between the IA and EA groups(94.7%and 94.7%,respectively;P=0.9891).There was no difference in the type of recurrence between the two groups.In addition,there were no significant differences in SSI incidence or the number of days on antibiotics;however,postoperative biological responses,such as the white blood cell count(10200 vs 8650/mm^(3),P=0.0068),C-reactive protein(6.8 vs 4.5 mg/dL,P=0.0011),and body temperature(37.7 vs 37.5℃,P=0.0079),were significantly higher in the IA group.CONCLUSION IA is an anastomotic technique that should be widely performed because its risk of intraperitoneal bacterial contamination and medium-term oncological outcomes are comparable to those of EA. | Hajime Kayano Nana Mamuro Yutaro Kamei Takashi Ogimi Hiroshi Miyakita Toshio Nakagohri Kazuo Koyanagi Masaki Mori Seiichiro Yamamoto | 2024 | World Journal of Gastrointestinal Surgery2024，16，3： | 0 |
| 8 | Current status and future perspectives for the treatment of resectable locally advanced esophagogastric junction cancer:A narrative review显示文摘Incidence rates for esophagogastric junction cancer are rising rapidly worldwide possibly due to the economic development and demographic changes.Therefore,increased attention has been paid to the prevention,diagnosis,and the treatment of esophagogastric junction cancer.Although there are discrepancies in the treatment strategy between Asian and Western countries,surgery remains the mainstay of treatment for esophagogastric junction cancer.Recent developments of perioperative multidisciplinary treatment may lead to better therapeutic effect,higher complete resection rate,and better control of the residual diseases,thus result in prolonged prognosis.In this review,we will focus on the treatment of locally advanced resectable esophagogastric junction cancer,and discuss the current status and future perspectives of the perioperative treatment including chemotherapy,radiation therapy,and immunotherapy,as well as the surgical strategy.Better understanding of the latest treatment strategy and future overlook may enable to standardize and individualize the treatment for esophagogastric junction cancer,thus leading to better prognosis for those patients. | Yoshiaki Shoji Kazuo Koyanagi Kohei Kanamori Kohei Tajima Mika Ogimi Kentaro Yatabe Miho Yamamoto Akihito Kazuno Kazuhito Nabeshima Kenji Nakamura Takayuki Nishi Masaki Mori | 2023 | World Journal of Gastroenterology2023，29，24： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员